Fig. 6: dl5-29 vaccination boosts total HSV-specific and ADCC but not neutralizing Ab.
Female C57BL6 mice were infected intranasally with 5 × 104 pfu/mouse of HSV-1 B3 × 1.1. Mice were monitored over 20 days for signs of disease and distress. At day 14 post-primary challenge, mice were bled retro-orbitally to obtain immune serum, which was tested for total HSV-1 specific IgG by ELISA and mice were assigned to vaccination groups based on HSV-1-specific IgG titers. Beginning on day 21-post-HSV-1 challenge, mice were prime-boost vaccinated at 3-week intervals with 5 × 106 pfu/mouse dl5-29 or an uninfected VD60 lysate. Serum was obtained on day 14 post-HSV-1 infection and 1 week following boost vaccination and assayed for a total HSV-2 IgG by ELISA (1:90,000 dilution); b neutralizing titer; and c fold-induction of FcγRIV activation (mFcγRIV ADCC Reporter Bioassay, Promega). Three weeks following boost vaccination, mice were challenged on the skin with 100 × LD90 (5 × 106 pfu/mouse) of HSV-2 clinical isolate, SD90. d Percentage survival following HSV-2 challenge. e At the time of death or sacrifice (D14 post-HSV-2 challenge), sacral ganglia were isolated and HSV-2 DNA was quantified by qPCR using serotype-specific primers. Mice that succumbed to HSV-2 superinfection are indicated by a crossed-through symbol. a–c Paired t-test comparing the post-vaccine versus post-HSV-1 antibody responses; d Gehan–Breslow-Wilcoxon test; e Fisher’s Exact Test. The asterisks (****) indicate p < 0.0001. **p < 0.01; ns indicates not significant. Data are shown as mean + SEM. n = 10 for dl5-29 and n = 5 for VD60.
